Can-Fite Reports Longer Overall Survival in Phase III Liver Cancer Study
RAMAT GAN, Israel, September 2, 2026 Can-Fite BioPharma Ltd. reported that blinded overall survival observed across the entire patient...
liver cancer
Advertisement
Can-Fite Advances Phase III Programs With FDA and EMA Status
RAMAT GAN, Israel, August 12, 2026 Can-Fite BioPharma Ltd. announced an update on the regulatory status of its two...
CancerVax Activates Human Killer T-Cells Against Cancer
LEHI, Utah, August 6, 2026 CancerVax announced a significant preclinical milestone with new in vitro findings demonstrating that its...
Leads Biolabs Advances Opamtistomig Phase II Trial in First-Line Liver Cancer
NANJING, China, August 6, 2026 Leads Biolabs announced that its Phase II clinical study evaluating Opamtistomig (LBL-024) in combination...
Elevar Receives FDA Complete Response Letter
FORT LEE, N.J., July 10, 2026 Elevar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has issued...
Advertisements
Can-Fite Reports Positive Phase 2a Namodenoson Safety Datar
Ramat Gan, Israel, July 1, 2026 Can-Fite BioPharma Ltd. announced that its Phase 2a clinical study evaluating Namodenoson in...
OriCell’s Ori-C101 Advances to Phase II Trial in Liver Cancer
SHANGHAI, China, June 8, 2026 OriCell Therapeutics has achieved a major regulatory and clinical milestone with the National Medical...
AngioDynamics Expands Medicare Access for NanoKnife Cancer Therapy
Latham, New York | May 28, 2026 AngioDynamics announced that Palmetto GBA has issued a final Local Coverage Determination...
AstraZeneca Unveils Major ASCO 2026 Cancer and Rare Disease Data
CAMBRIDGE, UK, 22 May 2026 AstraZeneca announced a major scientific showcase at the upcoming ASCO Annual Meeting 2026, highlighting...
Ribo and Boehringer Advance siRNA MASH Program
SUZHOU, China, May 6, 2026 Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB announced the achievement of...
Advertisement
